Last updated 5 days ago
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
350 patients around the world
Available in Argentina, United States
Merck Sharp & Dohme LLC
5Research sites
350Patients around the world
This study is for people with
Alzheimer disease
Dementia
Requirements for the patient
To 90 Years
All Gender
Medical requirements
- Has mild to moderate Alzheimer's Disease (AD) dementia (ie, Stage 4 or Stage 5 AD) based on the Alzheimer's Association Revised Criteria for Diagnosis and Staging of Alzheimer's Disease.Has a Mini-Mental State Examination (MMSE) score of 12 to 24 (inclusive).Is using acetylcholinesterase inhibitors (AChEI) therapy for management of AD dementia.Has a designated study partner who can fulfill the requirements of this study. The study partner will need to spend sufficient time with the participant to be familiar with their overall function and behavior and be able to provide adequate information about the participant needed for the study including, knowledge of functional and basic activities of daily life, work/educational history, cognitive performance, emotional/psychological state, and general health status.
- Has a known history of stroke or cerebrovascular disease.Has diagnosis of a clinically relevant central nervous system (CNS) disease other than AD dementia or other condition that negatively impacts cognition or cognitive status chronically.Has structural brain disease.Has a history of seizures or epilepsy.Has any other major CNS trauma, or infections that affect brain function (eg, Human immunodeficiency virus (HIV), syphilis, and/or neurological sequelae of Coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (COVID-19), including impact on cognition).Has major medical illness or unstable medical condition.Has a history of malignancy.Resides in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision (with protocol-specified exceptions).Has liver disease, including but not limited to chronic viral hepatitis, nonviral hepatitis, cirrhosis, malignancies, autoimmune liver diseases.
Sites
Instituto de Diagnóstico e Investigaciones Metabólicas - IDIM - sede centro - CABA
Recruiting
Instituto de Investigaciones Clínicas Mar del Plata
Recruiting
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Instituto Privado Kremer
Recruiting
Clínica Nuestra Señora de las Nieves
Recruiting
SponsorMerck Sharp & Dohme LLC
Study typeInterventional
Conditions
Alzheimer diseaseDementia
Requirements
To 90 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06721156
